Previous 10 | Next 10 |
IMX-120 utilizes proprietary, humanized antibody fragment to selectively silence disease-causing, overactive inflammatory bowel immune cells ImmixBio anticipates filing an IND for IMX-120 in 2023 The inflammatory bowel disease market is expected to reach $21.4 billion by 2...
Gainers: IceCure Medical (NASDAQ:ICCM) +16%. Atossa Therapeutics (NASDAQ:ATOS) +15%. G Medical Innovations (NASDAQ:GMVD) +11%. Exscientia (NASDAQ:EXAI) +10%. Immix Biopharma (NASDAQ:IMMX) +10%. Losers: Dermata Therapeutics (NASDAQ:DRMA) -...
Peloton Interactive PTON +32% Amazon buying Peloton would give it several benefits, including Prime boost: Truist. IceCure Medical (NASDAQ:ICCM) +17%. Origin Agritech (NASDAQ:SEED) +15% issues 2022 guidance of 300% revenue growth. Spirit Airlines SAVE +11% on Q4 results. H...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Short-squeeze stocks continue to be hot with traders and we’re going over five candidates that investors will want to watch today. Source: Alextype/Shutterstock.com Today’s list of short-squeeze candid...
LOS ANGELES, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, today a...
Manufactured IMX-110 to be utilized in both clinical trials: 2022 planned monotherapy IMX-110 Clinical Trial in soft tissue sarcoma (“STS”) 2022 planned combination IMX-110 + BeiGene anti-PD-1 tislelizumab Clinical Trial in advanced solid tumors An image of ...
3 Penny Stocks That Are Climbing During Today’s Trading Session After a week or so of less than stellar trading patterns for penny stocks and blue chips, today is a better day in the stock market. By mid-day trading, the S&P 500 pushed up by around 550 points, presenting a si...
IMX-110 + anti-PD-1 produced 63-day median survival in a genetic (KPC) pancreatic cancer mouse model in which mice develop their own pancreatic cancer and have an intact immune system Historically, 42-days is the median survival produced by a 4-drug combination of 2 chemotherapies and...
100% of patients treated with IMX-110 completed planned treatment cycles without drug-related interruptions in its ongoing Phase 1b/2a clinical trial IMX-110 is in clinical development as a monotherapy for soft tissue sarcoma (STS), a $3 billion market expected to grow to $6.5 billion...
3 Penny Stocks to Add to Your Watchlist Today With stock market futures eyeing a more positive trading day for penny stocks and blue chips, investors are excited about the near future. In the past few weeks, trading has been extremely volatile across the board. This is the result of the...
News, Short Squeeze, Breakout and More Instantly...
LOS ANGELES, CA, July 25, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”) (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and...
Lead site Memorial Sloan Kettering Cancer Center (MSKCC) Timing of milestone in-line with mid-2024 guidance Data from ex-US clinical trial reported at ASGCT 2024 showed a 92% overall response rate LOS ANGELES, July 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 4.6% to $128.28 on volume of 215,349,874 shares Zoomcar Holdings Inc. (ZCAR) rose 34.0% to $0.183 on volume of 204,010,215 shares Maxeon Solar Technologies Ltd. (MAXN) fell 3.5% to $0.1736 on volume of 2...